Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Regeneron
Regeneron
In showdown with Roche, Regeneron gears up for potential Eylea expansion amid Covid decline
Endpoints
Mon, 02/6/23 - 10:35 am
Regeneron
earnings
Eylea
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
Sun, 01/29/23 - 01:31 pm
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
Endpoints
Thu, 01/26/23 - 05:05 pm
Regeneron
Novartis
Eylea
drug delivery
patents
Lucentis
Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar
Endpoints
Tue, 01/10/23 - 06:40 pm
Coherus Biosciences
biosimilars
ophthalmology
Eylea
Regeneron
The Top New York Biopharma Companies Hiring Now
BioSpace
Mon, 01/9/23 - 10:58 pm
New York
hirings
Regeneron
Lundbeck
Schrödinger
Amgen files brief to Supreme Court ahead of oral arguments — with industry amicus support
Endpoints
Tue, 01/3/23 - 10:24 pm
Amgen
Sanofi
Regeneron
Supreme Court
legal
innovation
patents
Repatha
Praluent
10 clinical trials to watch in the first half of 2023
BioPharma Dive
Tue, 01/3/23 - 10:57 am
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle
Fierce Pharma
Mon, 12/12/22 - 10:21 am
Roche
ASH 2022
AbbVie
Regeneron
lymphoma
Lunsumio
glofitamab
Regeneron's Yancopoulos draws boos as he touts pharma innovation over cost considerations
Fierce Biotech
Thu, 12/8/22 - 11:22 pm
Regeneron
George Yancopoulos
innovation
Alzheimer's disease
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Fierce Pharma
Thu, 12/1/22 - 07:11 pm
Regeneron
Libtayo
non-small cell lung cancer
Bristol Myers Squibb
Yervoy
UK regulators warn of ocular side effects after treatment with Sanofi's Dupixent
Fierce Pharma
Thu, 12/1/22 - 10:43 am
Regeneron
Sanofi
Dupixent
UK
side effects
Regeneron, CytomX Ink Potentially $2B Bispecific Immunotherapy Deal
BioSpace
Thu, 11/17/22 - 12:05 pm
Regeneron
CytomX Therapeutics
bispecifics
cancer
Veloci-Bi
drug development
AstraZeneca and Sanofi win big as Europe's human medicines committee endorses approvals, label expansions
Fierce Pharma
Mon, 11/14/22 - 07:10 pm
Europe
AstraZeneca
Sanofi
COVID-19
cancer
GSK
Regeneron
Dupixent nears EU approval for rare skin disease prurigo nodularis
Pharmaphorum
Mon, 11/14/22 - 10:52 am
Sanofi
Regeneron
Dupixent
Europe
prurigo nodularis
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Endpoints
Wed, 11/9/22 - 10:38 am
Regeneron
Libtayo
non-small cell lung cancer
Keytruda
Merck
Amgen's Supreme Court bid answered in long-running Repatha patent feud against Sanofi, Regeneron
Fierce Pharma
Mon, 11/7/22 - 10:55 am
Amgen
Repatha
patents
Supreme Court
Sanofi
Regeneron
Insmed, Alnylam and others make Science's list of top 20 biopharma employers
Endpoints
Sun, 11/6/22 - 01:32 pm
employers
Inbsmed
Alnylam
Regeneron
Incyte
Regeneron scratches NGF inhibitor and cat allergy therapy from pipeline
Fierce Biotech
Thu, 11/3/22 - 11:53 am
Regeneron
chronic pain
cat allergy
Regeneron, Bayer's Eylea nabs six months of pediatric exclusivity as competition waits to enter the market
Endpoints
Mon, 10/24/22 - 11:10 pm
Regeneron
Bayer
Eylea
pediatric exclusivity
biosimilars
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »